(Albany, US), September 11, 2026, DelveInsight’s Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast 2034 report delivers an in-depth understanding of Plaque Psoriasis, historical and forecasted epidemiology, as well as Plaque Psoriasis therapeutics market trends across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Request to unlock the CAGR of the Plaque Psoriasis Market: https://www.delveinsight.com/report-store/plaque-psoriasis-market

Key Facts of the Plaque Psoriasis Market Report

• The Plaque Psoriasis market is expected to strengthen through the forecast period (2024–2034) as disease awareness increases and more effective interventions are developed.

• The Plaque Psoriasis companies developing and marketing therapies in the treatment landscape include Dermavant Sciences, IQVIA Biotech, UCB Biopharma, Parexel, Samsung Bioepis, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals, Maruho, Novartis, AstraZeneca, Pfizer, and others.

• Strong clinical success of biologics targeting the TNF-α, IL-17, and IL-23 pathways has transformed treatment outcomes, driving higher adoption and sustained demand for advanced therapies.

• Development of next-generation oral small molecules and novel topical formulations is expanding treatment choices beyond injectable biologics, improving patient adherence.

• In May 2025, the FDA approved SELARSDI (ustekinumab-aekn) as an interchangeable biosimilar to Stelara (ustekinumab) for adult and pediatric patients with plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; it became available in all matching presentations starting April 30, 2025.

• In April 2025, the FDA designated YUFLYMA (adalimumab-aaty), a high-concentration, citrate-free formulation, as an interchangeable biosimilar to Humira (adalimumab) across multiple inflammatory indications.

• A robust late-stage pipeline, including PDE4 inhibitors and other novel mechanisms of action, is expected to sustain market momentum through 2034.

Plaque Psoriasis Overview

Plaque psoriasis is a chronic autoimmune skin condition characterized by red, itchy, and scaly patches that can significantly impact a patient’s quality of life. It is the most common form of psoriasis and represents a dynamic and essential segment within the pharmaceutical and healthcare industry, with the treatment market having witnessed remarkable growth in recent years, fueled by advancements in medical research and the development of innovative therapies.

Explore how targeted biologics and novel oral therapies are transforming the future of the Plaque Psoriasis Market Insights

Plaque Psoriasis Therapies and Key Companies

Key Plaque Psoriasis Companies Include:

• Dermavant Sciences GmbH

• IQVIA Biotech

• UCB Biopharma SRL

• Parexel

• Samsung Bioepis Co., Ltd.

• Durect

• Astellas

• Biogen

• Dow Pharmaceutical Sciences

• Shire

• Zalicus

• AbbVie

• Santalis Pharmaceuticals Inc.

• Maruho Co. Ltd.

• Novartis

• AstraZeneca

• Pfizer

• Others

Discover detailed company profiles, pipeline strategies, licensing activities, and competitive benchmarking in DelveInsight’s Plaque Psoriasis Market Report

Plaque Psoriasis Marketed Therapies

Current treatment approaches span a range of severities and modalities:

• Topical Treatments – Creams, ointments, and gels containing corticosteroids, retinoids, or vitamin D analogs, used to reduce inflammation and control excessive skin cell growth in mild disease.

• Biologic Therapies – Agents targeting the TNF-α, IL-17, and IL-23 pathways, including interchangeable biosimilars such as SELARSDI (ustekinumab-aekn) and YUFLYMA (adalimumab-aaty), used in moderate-to-severe disease.

Plaque Psoriasis Emerging Therapies

Emerging candidates in late- and mid-stage development include PDE4 inhibitor drugs and other novel oral small molecules and topical formulations, designed to offer effective alternatives to injectable biologics and broaden treatment choices across disease severities.

Get a detailed understanding of the evolving Plaque Psoriasis treatment landscape

Plaque Psoriasis Market Drivers

• Rising disease prevalence alongside better disease awareness and improved diagnostic practices, expanding the addressable patient pool.

• Advancements in targeted biologic therapies, with strong clinical success across TNF-α, IL-17, and IL-23 pathways.

• Expansion of novel oral and topical agents, offering alternatives to injectables and improving patient adherence.

• Increasing treatment uptake in moderate-to-severe patients as the systemic burden and quality-of-life impact of the disease are more widely recognized.

• Growing healthcare expenditure and improving reimbursement frameworks supporting patient access to high-cost therapies.

• A robust late-stage pipeline with multiple candidates, including long-acting agents and novel mechanisms of action.

• The chronic nature of plaque psoriasis, driving recurring therapy use and steady long-term revenue generation.

• Rising patient and physician awareness through educational initiatives, patient advocacy, and evolving treatment guidelines.

Plaque Psoriasis Market Barriers

• Reimbursement and access barriers, particularly for high-cost biologic and emerging therapies.

• Variability in treatment practices and guidelines across the US, Europe, and Japan.

• Competitive pressure from biosimilars entering the market alongside originator biologics.

• Ongoing need for improved long-term compliance and patient adherence across therapy classes.

Scope of the Plaque Psoriasis Market Report

• Study Period: 2020–2034

• Forecast Period: 2024–2034

• Coverage: 7MM (United States, EU5 Germany, France, Italy, Spain, and the United Kingdom, and Japan)

• Key Plaque Psoriasis Companies: Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co. Ltd., Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc., Maruho Co. Ltd., Novartis, AstraZeneca, Pfizer, and others

• Therapeutic Assessment: Current marketed and off-label therapies, and late- and mid-stage (Phase III and Phase II) emerging pipeline drugs, including PDE4 inhibitors

• Market Dynamics: Market drivers, market barriers, and unmet needs

• Competitive Intelligence Analysis: SWOT Analysis, PESTLE Analysis, Porter’s Five Forces, BCG Matrix, and Market Entry Strategies

• Additional Coverage: Epidemiology, Diagnosed Patient Pool, Drug Uptake, Clinical Trials, Reimbursement, and KOL Views

Discover the latest Plaque Psoriasis Market Landscape

DelveInsight is a leading Business Consulting and Market Research firm focused exclusively on the life sciences industry. The company provides comprehensive market intelligence, competitive intelligence, epidemiology forecasting, pipeline assessment, pricing and reimbursement analysis, and healthcare consulting services that help pharmaceutical, biotechnology, and medical device companies accelerate strategic decision-making and commercial success.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: Send Email
Phone: 09650213330
Address:A-1 NV 89107
City: delhi
State: Indiana
Country: India
Website: https://www.delveinsight.com/